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Pancreatic islet transplantation after upper 
abdominal exenteration and liver replacement 
ANDREAS G. TZAKIS CAMILLO RICORDI RODOLFO ALEJANDRO 
YlJUNZENG JOHNJ. FuNG SATORUToDO 
ANrnONY J. DEMETRIS DANIEL H. MINTZ THOMAS E. STARZL 
Nine patients who became diabetic after upper-
abdominal exenteration and liver transplantation 
were given pancreatic islet-cell grafts obtained 
from the liver donor (eight cases). a third-party 
donor (one). or both (four). Two patients were 
diabetic when they died of infections after 48 and 
109 days. as was a third patient who died of tumour 
recurrence after 178 days. The other 6 are alive 
101-186 days postoperatively. and five are insulin-
free or on insulin only during night-time parenteral 
alimentation. C-peptide increased 1·7to 3·3 fold in 
response to intravenous glucose in these five 
patients who have had glycosylated haemoglobin 
in the high normal range. However. the kinetics of 
the C-peptide responses to intravenous glucose in 
all eight patients tested revealed an absent first-
phase release and a delayed peak response 
consistent with transplantation and/or 
engraftment of a suboptimal islet cell mass. The 
longest survivor. who requires neither parenteral 
. -iI!Lmentation nor insulin. is the first unequivocal 
exalTipte . .of successful clinical islet-cell 
transplantation. 
Lancet 1990; 336: 402-05. 
Introduction 
Long-term reversal of hyperglycaemia following islet 
transplantation has been reported in animal models of 
diabetes, I but not in patientsIO~D though Scharp's group in St 
Louis' has lately reported one encouraging case to an 
American Diabetes Association meeting (see]AMA 1990; 
264: 427). Clinical failure has been attributed to poor 
harvesting and organ preservation techniques, inadequate 
procedures for isolating and purifying islets, and failure to 
control islet-directed inunune destruction. However, 
improvements in techniquef'·7 have lately increased the yield 
and purity of functionally competent islet grafts,l.5.8-tO and 
the potent new inununosuppressive agent FK 506 has made 
control of rejection easier. Il •11 Using these advances, we have 
given islet allografts to patients rendered apancreatic by 
upper-abdominal exenteration. 13•1' 
Patients and methods 
Patients 
Nine patients aged 8-58 years underwent upper-abdominal 
exenteration for tumours too extensive to be removed with less 
drastic procedures. Liver, pancreas, spleen, stomach, duodenum. 
proximal jejunum, and tenninal ileum and, in three cases, the 
ascending and transverse colon were removed.1lJ4 A cadaveric liver 
orthotopic allograft was done" and the graft portal vein was 
anastomosed to the recipient superior mesenteric vein. 
Arterialisation was from the recipient aona or coeliac axis (fig I). A 
140 catheter with a heparin lock was placed in a superior mesenteric 
venous tributary. Bowel continuity was re-established and biliary 
drainage was via a choledochojejunostomy (fig I) . 
Organ proc!jrement 
The cadaveric donors were the same ABO type as the recipient 
except for the second pan=s donor (type 0) for patient 8, who was 
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Fig 1-liver and pancreatic islet transplentation after upper 
abdominal exenteration. 
rype B. HLA matching was random, and the antigens matched were 
zero or one of a possible 4 in the 4 cases in which romplete 
infonnation was available. There were two positive cytotoxic 
cross-matches (patients 2 and 4). . -
The livers and pancreases were obtained from multi~rgan 
donors.U3 In situ perfusion of the abdominal aorta was with 
1500-2000 mJ of University of Wisconsin solution (UWS). An 
additional 500-1000 mI UWS were infused directly into the liver via 
the ponal vein which was encircled below the catheter tip to prevent 
retrograde leakage. Venous hypertension of the pancreas was 
avoided by venting the ponal and/or splenic vein. The specimens 
were immersed in UWS and packed in ice. 
The pancreas of the liver donor was the source of the primary islet 
graft for eight patients. Four recipients were given islets from a 
second donor 1-2 days after the first infusion. Patient 7 was given his 
single islet infusion from a third-party donor I day after the 
principal operation. 
Islet preparation and administration 
Cold ischaemia time of the thirteen pancreases averaged 8 h 
(range S-14h). The islets were isolated. I. The pancreatic duct was 
cannulated and 25()-300 mI Hank's solution containing 1-2 mg/ml 
collagenase (Boehringer-Mannheim) was injected. The separated 
islets were purified with a disrontinuous gradient of 'Ficoll' powder 
(Sigma) in Euro-Collins solution,S at specific densities of 1· lOS, 
I-('96, and H137. A COBE 2991 cell separator (COBE 
Laboratories, Lakewood, Colorado) was used for purification.'s;, 
Islet preparation took 4 h on average. 
The islet cells were suspended in 2SO mI Hank's solution; 100 !li 
samples were stained with dithizone'7 to assess total islet yield, 'us;_ 
which was standardised. Islet particles varied in size from SO to over 
250 1Iffi. The heterogenously sized islets were converted to "ISO J,Un 
equivalents",''' and the contribution of the different size groups to 
the total islet volume was then expressed in !li. 
The preparation was pelleted and suspended in 100 mI Hank's 
solution containing 10% human albumin and infused into the 
ponal vein catheter over 20-30 min. Ponal venous pressure was 
measured and ponal flow was assessed by colour doppler 
ultrasonography. When not in use, the ponal vein catheter was 
flushed every 6 h with 2 mI saline containing hepariI) 100 units/mi. 
The catheter was extracted after completion of the-~ 
infusion( s). 
Postoperative management 
All patients were maintained on continuous parenteral 
hyperalimentation for about 2 weeks after surgety, with solutions 
containing 20-25% dextrose, 10-20% lipids, 3'S-5'0% crystalline 
aminoacids, electrolytes, trace metals, and vitamins including folic 
acid. Subsequendy, the patients ate as desired. 15 to 40 non-enteric 
ooated tablets per day of pancreatic extract (pancrelipase U SF) were 
administered with meals. The daytime diet was supplemented with 
1000-1500 kcal parenteral alimentation overnight until the body 
weight was stable without intravenous supplementation. Regular 
insulin C'Humulin'; Eli Lilly) was always added to the intravenous 
solutions to maintain the blood glucose at S-7 mmol/1. 
Immunosuppression with FK 506 began with intravenous doses 
0[0'075 mg;kgevery 12 h followed byO·15 mgikgora11y every 12 h. 
The dose was adjusted on dinical grounds and by monitoring 
plasma FK 506 levels. Rejection was treated with a single 
intravenous injection of Ig hydrocortisone or methylprednisolone; 
that failed in two patients, who were given OKT3 IOmg daily for 5 
days ('Orthoclone'; Ortho Pharmaceutical). Only patient 3 was 
given maintenance steroid therapy. 
Assessment of islet function 
BasaJ and stimulated (6 min after I mg glucagon intravenously) 
C-peptide levels were measured after the exenteration and liver 
tranSplantation but before infusion of islets. There were no 
C-peptide responses. After islet transplantation, blood glucose and 
C-peptide were monitored. An intravenous glucose tolerance test 
(IVGTT), selected as a provocative test of C-peptide secretion, was 
done every 2-4 weeks. Glycosylated haemoglobin (HbA1c) was 
measured before and every 6 weeks after transplantation. 
TABLE I-RECIPIENTS AND OUTCOME· 
No 
I (I5,Fl 
2(8,M) 
3 (55,M) 
4 (36, F) 
5 (58,M) 
b (52, F) 
7 (46,M) 
8 (44, Fl 
9 (33, Fl 
I 
I 
I 
I 
I 
I 
i 
Periopefatlve complications 
None 
Moderate reJttOon (liver) day 19, treated WIth 
FK506 
Seven: rejecnon (liver) day 18, treated with 
OKTI 
Oinical rejection day 5, treated with OKT3; 
intractable cytomcgalonrus mfecoon and 
re5puatory failure 
None 
In\1ISive cytomegalovirus mfection, 
c:andidacmia 
None 
Sepsis with transIent renal failure 
None 
"Follow-up to 15 July 1990 
I 
I 
I 
Insulin 
requirementst 
NIR-S 
IR 
IR 
IR 
NIR-S 
IR 
NIR-S 
NIR-V 
NIR-S 
Outcome 
Full activity 
Died 178 days 
Died 48 days post-
tr.Insplant 
Died 109 days post-
tr.InSplant 
Full activity 
R<cuperating at home 
Full activity 
Full activilV 
Full actInty 
Donor 
age(5) 
18 
7 
36 
IQ 
26,19 
18.<\0 
18 
17,35 
31.50 
Details of Islet grafts 
I 
I 
I 
I 
I 
Islets 
( x 10') 
474 
562 
205 
289 
369,209 
105, 153 
285 
459,267 
205, 127 
I 
I 
I 
i 
Endocrine 
vol (Ill) 
839 
993 
363 
510 
653,369 
186,270 
504 
811,472 
363,224 
fNIR-S" non-Insultn reqUIring. stabte, preprandlal blood glucose < 7,8 mmol/l HbA,c < 6·2'% (3 9-5 9 normal) ketOSIS ,eslstant; NIA· U'" non-msuhn requiring, unstable 
preprlnchal blood glucose 7·8-11 2 mmol'l HbA, c .... 7%. ketOSIS re5rstant IR = Insultn requIring 
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I 
I 
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Results 
Survival 
Patient 2 died of recurrent cancer after 178 days. Patients 3 
and 4 died with rejection, sepsis, and multiple organ failure 
(table I). All three were insulin dependent. No islets were 
found post mortem in the liver of patient 3; several 
well-granulated islets were identified in patient 4 by indirect 
immunoperoxidase stain. Necropsy was not done in patient 
2. Three patients recovered from the procedures despite 
liver rejection (patient 2), cytomegalovirus and candida 
infections (patient 6), and systemic enterobacter sepsis 
(patient 8). All six survivors have normal liver function and 
no evidence of tumour recurrence after 3-6 months of 
follow-up. 
Pancreatic islet yield 
The fInal preparations constituted a packed volume ofless 
than 3 mi. The number of 150 IJIll islet equivalents varied 
from 105 000 to 562000, corresponding to a volume of 
endocrine tissue of 186-993 IJ.l (table I). The intraportal 
injection(s) did not affect portal pressure and 
haemodynamics or cause any adverse effects. In patient 6, a 
liver biopsy sample taken 17 days post-transplantation 
contained a morphologically normal islet in one portal triad 
of the hepatic graft. 
Islet function 
No patient acquired ketonuria. The three who died were 
not able to eat regularly and were given insulin continuously 
during total parenteral alimentation except at the time of 
IVGTT. 
Patient 1 is insulin-free after more than 6 months and has 
not required parenteral nutrition support since the fourth 
postoperative month. She lives a normal life and has gained 
3 kg over the past 2 months. Patients 5, 7,8, and 9 are not on 
exogenous insulin, except during the night-time parenteral 
hyperalimentation which has been required periodically to 
TABLE II-FASTING AND NON·FASTING BLOOD GLUCOSES 
AND GLYCOSYLATED HAEMOGLOBIN IN SIX SURVIVING 
PATIENTS 
Blood glucose (fasting) Blood glucose 
Case (mmol/I) (non· fasting) (mmol/I) HbA,c (%) 
I 
5 
6 
7 
8 
9 
~mean (and SEM) 
--
54 (0'5) 
5·9 (0,2) 
8'7(0'5) 
57 (05) 
7·2 (0'7) 
7·6 (0,3) 
5·8 (0,5) 6·0 
6·1 (0,2) 58 
10·1 (0,3) 5·8 
75 (0,5) 5·1 
10·8 (05) 6·6 
83 (0'3) 5·6 
TABLE III-C·"P"EPTIDE RESPONSE TO 05 g/kg INTRAVENOUS 
GLUCOSE 
Follow·up 
C·peplide (pmol/ml) 
Week post· transplant 
Case (days)* Basal Peak of last test 
1 185 0·96 28 16 
2 178 (dead) 0·66 114 96 
3 48 (dead) 0·78 090 1·5 
4 109 (dead) 222 2·52 5 
5 153 168 4-<J8 12 
6 121 1·68 3·6 26 
7 118 1·0 3·3 7 
8 102 5-ot 8·4 6 
9 101 14 3·24 2·4 
'ToJuly 15. 1990 
tSefUm creatmlne 354 ~mol/f at time of test 
0 30 5.5 
I 5.0 () I 
°24 4.5 
"'0 
.., 
i "'0 4.0 -< a E 3.5 .., 
:18 ~ 3.0 "'0 CJ) ;;::: 
0 2.5 0 g 12 r "-
..I 2.0 ;;::: 
0 1.5 .s 
< • ~ 6 1.0 I CJ) 
< 0.5 • ..I Il. 0 0.0 
0 30 60 90 120 150 180 
TIME (MINUTES) 
Fig 2--Glucose disappearance and C-peptide respons. after 
administration of intravenous glucose (0'5 g/kg) in patients 1. 
5.7.9. 
prevent weight loss. Patient 6 is on insulin 0·1 units/kg daily 
and is a treatment failure. 
The fasting blood sugar levels in the 5 patients who were 
insulin independent and who were tested after withdrawal of 
night -time parenteral alimentation for several days averaged 
less than 7·8 mmol/l, and random non-fasting levels during 
the day time were below 8·4 mmol/l in four. HbA1c levels 
were high normal in four patients and slightly abnormal in 
the other (table II). 
C-peptide was detectable in plasma of all patients for as 
long as they were studied. C-peptide responses to 
intravenous glucose were demonstrable in all patients, the 
latest results being summarised in table Ill. C-peptide 
kinetics are shown in fIg 2 for four patients not on daytime 
exogenous insulin (patient 8 was excluded from the 
computations because of a high basal C-peptide level, 
attributed to renal failure). The peak C-peptide response 
was delayed at 60 min, a 5-10 min peak being nonnai, and 
blood glucose did not return to basal levels until 150-180 
mm. 
Discussion 
The conditions of these procedures have both advantages 
and disadvantages for the evaluation of islet 
allotransplantation. The foremost advantage is the 
assurance that any islet function was from the graft, all native 
pancreas having been removed. In all nine patients there was 
no C-peptide response to glucagon in the brief interval 
between surgery and the islet infusion. A hypothetical 
advantage, for which there is experimental SUpport,Zl is that 
the immune barrier to islet acceptance might be lowered by 
the presence of a liver from the same donor, as in eight of the 
cases. HowevJlr, the patient (case 7) whose pancreas was 
procured from a third-party donor achieved one of the best 
results; in this case the pancreas donor and the recipient had 
a complete HLA mismatch except for one DR antigen. 
There are also disadvantages. All the recipients had severe 
weight loss and required long periods of parenteral 
alimentation with solutions that contained insulin. Even 
with the resumption of diet, parenteral infusions overnight 
were frequently needed to prevent malnutrition. These were 
stopped for several days or weeks when metabolic tests were 
done so that the patients were free of exogenous insulin. 
Postoperative infections and other complications had a 
potential confounding effect on the results in half the cases, 
and patient 2 had early tumour recurrences which precluded 
-------------------
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metabolic stability or long survival. Patients 2 and 4 had 
positive cytotoxic cross-matches with their liver-islet 
donors. Although their livers functioned throughout the 
survival period, they ultimately became diabetic. 
Despite the difficulties, early islet allograft function was 
demonstrable in every recipient. This function has been 
sustained in five patients. However, no patient has normal 
insulin secretory kinetics: even where fasting and random . 
non-fasting blood sugar was normal first-phase release in 
the C-peptide responses to intravenous glucose was absent 
and the peak response was delayed. These findings are 
characteristic in animal models of reduced islet-cell 
mas~ and in the prolonged prodrome of;;pontaneous 
type I diabetes mellitus.Z5 They also resemble the results in 
pancreatectomised dogs given inadequate numbers of islet 
allografts.16 The dog studies had suggested that correction 
might be more complete in patients given the islets from two 
donors but this did not happen, and 2 of the best clinical 
results (cases 1 and 7) were in patients given islets from 
single pancreases. Silent rejection of islets without 
commensurate injury to the liver graft is one possibility, 
islets being highly immunogeniC.l - 5 FK 506 can be 
diabetogenic,l7 and an even greater vulnerability to 
hyperglycaemia is caused by steroid therapy. However, only 
one of our patients was on maintenance prednisone. 
This series suggests that islet tIahsplantation in man is 
feasible but it is too early for widespread clinical trials to be 
justified. The metabolic correction is incomplete and 
finding multiple islet donors-should this in fact prove to be 
necessary-will make islet transplantation impracticable on 
a large scale, unless procedures for long-term culture or 
ayopreservation of islets are developed. 
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grant DL 29961 and DK 25802 from the National Institutes of Health, and 
the Diabetes Research Institute FOWldation, Miami, Florida. 
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BOOKSHELF 
The Management of Pain 
2nd ediricm. John J. Bonica. Philadelphia and London: Lea and 
Febiger. 1990. Pp 2184 (two vols). S22S/£I54.69. ISBN 
0-812111222. 
The front cover of each volume of Professor Bonica's 
massive text is adorned with a photograph of the sculpture 
"Laocoonte", now housed in the Vatican. The hero and his 
two sons writhe in the coils of a serpent, their faces and their 
postures indicating anguish rather than physical effort. One 
cannot help feeling, with some impatience, that the snake is 
not so big and that with a little effort the men could shrug it 
off. A similar impatience may colour the attitude of a doctor 
to the patient with a pain that defies diagnosis or treatment. 
That impatience-that sense that the sufferer could surely 
shrug it off if he would-is the very attitude that Bonica has 
fought against from the first edition of this major work in 
1953. The proper management of pain is for him "the most 
important obligation, the main objective, and the crowning 
achievement of every physician". 
The sculpture depicts Laocoon as twice the size of his 
offspring, despite their adult proportions. The reverse is the 
case with the book, the second edition being more than twice 
the size of its forbear. It has not, however, changed in its 
compassionate and consistently positive attitude to the 
patient with pain. The style remains leisurely with plenty of 
space for case histories and thumbnail sketches of the most 
obscure or unlikely causes of pain (relapsing polychondritis, 
medullary sponge kidney, spider bites). Bonica has recruited 
a large and distinguished team of contributors to update and 
" , 
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